NEW YORK, Dec. 3 /PRNewswire-FirstCall/ -- Immtech Pharmaceuticals,
Inc. (Amex: IMM) announced today that it will present at the Bank of
Montreal (BMO) Capital Markets Focus on Healthcare Conference. On Tuesday,
December 4, 2007 at 11:00am Eastern Time, Immtech is scheduled to present
in the Biotechnology Room 4.04 -- the Millennium Broadway Hotel at 145 West
44th Street, New York City.

About Immtech Pharmaceuticals, Inc.

Immtech Pharmaceuticals, Inc. is focused on developing and
commercializing drugs to treat infectious diseases, and the Company is
expanding its targeted markets by applying its proprietary pharmaceutical
platform to treat other disorders. Immtech has advanced clinical programs
that include new oral treatments for pneumocystis pneumonia (PCP), malaria,
and trypanosomiasis (HAT or African sleeping sickness), and a well defined,
expanding library of compounds targeting drug-resistant Gram-positive
bacteria, fungal infections, Hepatitis C and other serious diseases.
Immtech holds the exclusive worldwide licenses to certain patents, patent
applications and technology for products derived from a proprietary
pharmaceutical platform. For additional information, please go to
http://www.immtechpharma.com

"Safe Harbor" Statement under the Private Securities Reform Act of
1995: Statements in this press release regarding Immtech Pharmaceuticals,
Inc.'s business, including the future prospects for PCP, which are not
historical facts are "forward- looking statements" that involve risks and
uncertainties. Actual results could differ materially from these
forward-looking statements. Factors that could cause or contribute to such
differences include, but are not limited to, those discussed under the
headings "Management's Discussion and Analysis of Financial Condition and
Results of Operations" and "Risk Factors" in Immtech's annual report on
Form 10-K for the year ended March 31, 2007 and in its other SEC filings
and include: (i) Immtech's ability to develop commercially viable products;
(ii) Immtech's ability to achieve profitability; (iii) Immtech's ability to
retain key personnel; (iv) the ability of Immtech's scientists and
collaborators to discover new compounds; (v) the availability of additional
research grants; (vi) Immtech's ability to obtain regulatory approval of
its drug candidate, including PCP; (vii) the success of Immtech's clinical
trials; (viii) dependence upon and contractual relationship with partners;
(ix) Immtech's ability to manufacture or to have a third party manufacture
its drug candidate at a reasonable cost; (x) Immtech's ability to protect
its intellectual property; (xi) competition and alternative technologies;
(xii) Immtech's ability to obtain reimbursement from third party payers for
any product it commercializes; and (xiii) potential exposure to significant
product liability.

(Date:10/10/2017)... ... October 10, 2017 , ... ... program has won a US2020 STEM Mentoring Award. Representatives of the FirstHand program ... in Volunteer Experience from US2020. , US2020’s mission is to change the trajectory ...

(Date:10/10/2017)... 10, 2017 SomaGenics announced the receipt of ... develop RealSeq®-SC (Single Cell), expected to be the first ... (including microRNAs) from single cells using NGS methods. The ... to accelerate development of approaches to analyze the heterogeneity ... "New techniques for measuring levels of mRNAs in individual ...

(Date:4/11/2017)... DUBLIN , Apr. 11, 2017 Research ... Tracking Market 2017-2021" report to their offering. ... The global eye tracking market to grow at ... The report, Global Eye Tracking Market 2017-2021, has been prepared based ... report covers the market landscape and its growth prospects over the ...

(Date:4/5/2017)... The Allen Institute for Cell Science today announces ... portal and dynamic digital window into the human cell. ... application of deep learning to create predictive models of ... a growing suite of powerful tools. The Allen Cell ... publicly available resources created and shared by the Allen ...